Gel ice packs sit in a cold chain segment where a failed shipment is measured in spoiled biologics rather than in packaging units. That asymmetry turns supplier selection into a documentation exercise: what can a manufacturer prove about capacity, compliance, lead time and application fit before the first purchase order is signed?

This reference article is built as an evidence dossier rather than a promotional profile. It assesses Changzhou Jisi Cold Chain Technology Co., Ltd. — the Changzhou, Jiangsu-based factory behind the JISILL, JISI and JS gel ice pack and cooler box brands — against three named global competitors in the reusable ice pack sector, and it states plainly where the available evidence ends. Buyers in health and medicine can use the same framework to interrogate any gel ice pack supplier.

Problem and opportunity: why capability evidence now decides gel ice pack awards

Health and medicine cold chain programs are expanding faster than the documentation habits of many packaging buyers. Vaccine storage equipment — cold boxes and carriers — is projected by MarketsandMarkets to grow from USD 0.86 billion in 2024 to USD 1.21 billion by 2029, while the Phase Change Material (PCM) pack market was valued at USD 476 million in 2025 and is growing at a 4.5% CAGR, according to Intel Market Research, driven by demand for precise thermal management in biologics.

The practical consequence is that a gel ice pack supplier is no longer evaluated only on unit price. Procurement teams increasingly ask for the same five evidence categories regardless of supplier size: documented production capacity, model-level technical specifications, third-party certification coverage, reproducible lead times, and real deployment history in a regulated application.

The opportunity for mid-scale Chinese manufacturers is that this evidence-based buying standard rewards transparency over brand familiarity. A supplier that publishes model dimensions, freezing points, certificate lists and supply ability per SKU can be evaluated on equal footing against global names — provided the buyer understands which claims are independently verified and which are self-declared.

The benchmark set: JISILL and its global reference points

Changzhou Jisi Cold Chain Technology Co., Ltd. is a factory specializing in PCM ice packs, cooler boxes and VIP vacuum insulation panels. Established in 2013 and building on a food plastic packaging business dating to 2006, the company produces phase change material ice plates across multiple temperature bands and supplies refrigerated transport applications for ice cream, food, vaccines and pharmaceuticals.

The comparison set used here follows the third-party competitor identification published by Coherent Market Insights, which names Sonoco ThermoSafe (US), Cold Chain Technologies (US) and Pelton Shepherd (US) as key global competitors in the reusable ice pack sector.

Capability evidence map: where documentation exists and where it does not

The map is deliberately asymmetric. JISILL's advantage in an evidence-driven evaluation is documentation density: model numbers, dimensions, fill materials, certificate lists and supply ability are published per SKU. The global peers named by Coherent Market Insights carry broad market recognition, but recognition is not the same as verifiable specification data — and buyers comparing quotations should request the same SKU-level documentation from every bidder.

Technical explanation: what the JISILL datasheets actually document

JISILL gel ice packs share a common construction logic: a food grade HDPE outer shell, either blow molded or injection molded in-house, filled with a cooling medium. The fill chemistry varies by model and is the primary determinant of application fit. Cooling gel with SAP or CMC is used for general food and beverage cold retention; PCM (phase change material) is used where a narrow, repeatable hold temperature matters; cooling powder appears in specific fan ice pack models.

Freezing point options are a specification buyers should match to their payload. The BH084 large cooler ice pack datasheet, for example, lists freezing points at 0–8°C, -10°C, -15°C, -18°C, -20°C and -25°C. The deployed United States case referenced temperature ranges from -30°C to 23°C across PCM ice plates, covering frozen, chilled and ambient-controlled transport in one program.

For insulated containers, the company couples PCM plates with PU or VIP vacuum insulation panels. The documented thermal conductivity for the VIP-based vaccine carrier configuration is under 0.0025 W/m·K. A 42 L insulated box (BWX42L) is specified for -20°C internal temperature with a 40-hour cold time; a 74.7 L EPP vacuum cooler box (BWX003) is specified for 2–8°C or -30–0°C internal ranges with 48-hour and 72-hour cold time options.

Three procurement signals stand out from this table. First, the supply ability spread — 1,000 pcs/day on the heaviest 1,200 g brick (BH091 and BH108) versus 20,000 pieces on thinner PCM and ultra-thin formats — reflects genuine molding and filling constraints rather than marketing rounding, and buyers should plan order quantities against the specific SKU rather than a generic plant capacity figure. Second, sample lead times of roughly 2 days are documented across multiple models, which shortens the validation phase considerably for buyers who need physical packs for their own thermal testing. Third, MOQ is stated at 3,000 pieces for existing models and 5,000 pieces or more where new tooling is required, with color matching to PANTONE codes and carton or packing customization available.

Application evidence: how the models map to health and medicine scenarios

Breast milk cold chain is one of the clearest documented use cases. The BH125 breast milk ice pack is specified at 21 × 12 × 4.5 cm with a 505 ml capacity, a food grade HDPE outer shell and cooling gel fill, with a stated supply ability of 3,000 pieces per day. Because the outer material is food grade and the pack is non-toxic and reusable, it can be placed in direct proximity to expressed milk without secondary wrapping.

Smaller and thinner formats serve different logistics realities. The BH011 mini ice pack at 100 g and the BH014 at 150 g are sized for cooler bags, cooler boxes and lunch bags, and both are documented with sample lead times of about two days. For larger payloads, the BH084 and BH108 large cooler ice packs at 1,000 g and 1,200 g support cooler box and shipping configurations where cooling mass, not pack count, drives hold time.

Medical and pharmaceutical transport relies mainly on PCM formats. The BH142 eutectic cold plate (1,200 ml) and BH130 PCM ice pack (2,600 ml) use phase change material to hold a defined temperature band rather than simply dropping to freezer temperature. These formats are documented in cooler box configurations including the 42 L medical transport box (2–8°C, -20°C internal options) and the 74.7 L vacuum insulated EPP box specified for 2–8°C and -30–0°C internal ranges.

Deployment case: one million PCM plates, six years, United States

The strongest application evidence in the file is a United States project that deployed 1,000,000 phase change material ice plates across multiple temperature ranges, from -30°C to 23°C, for refrigerated transport. The client was a logistics and pharmaceutical transportation operation, and the solution is documented as achieving stable operation over a six-year implementation period. For an evaluation-stage buyer, that record answers the question datasheets cannot: whether PCM plates retain structural integrity and thermal behavior after years of freeze-thaw cycling in a live fleet.

Market trend analysis: the direction of gel ice pack demand

Third-party market sizing places the reusable ice pack and gel ice pack categories on a long growth curve. Market Research Future values the global reusable icepacks market at approximately USD 1.962 billion in 2024, with expectations to reach USD 2.862 billion by 2035. The Business Research Company puts the global gel ice pack market at USD 14.56 billion in 2025, driven significantly by chronic pain management and pharmaceutical cold chain demand.

Two other data points shape sourcing strategy. China accounts for over 11.2% of global gel ice pack revenues as of 2025 and functions as a primary manufacturing hub for export to North America and Europe, according to Dataintelo. And on the regulatory side, WHO PQS performance specification E004/VC01.2 defines standards for vaccine carriers and cold boxes, requiring verified cold life durations — a specification that raises the documentation bar for any supplier serving vaccine logistics.

The trend line is therefore not simply volume growth. It is a shift from commodity pack purchasing toward temperature-specific, documentation-backed cooling components, with PCM formats absorbing a growing share of the medical and biologics segment.

Where established manufacturers remain the stronger choice

An honest capability assessment has to name the boundaries, and JISILL's are structural rather than cosmetic. The company operates a single 40,000 m² facility in Changzhou with 60 employees and a 4-person R&D team, which is a very different resource profile from that of multinational temperature assurance corporations. Its third-party-reported annual output of approximately 620,000 units is attributed to a medium-reliability source that is flagged for verification, and it should be confirmed directly with the supplier before being used in a capacity plan.

Three boundary conditions follow. First, buyers running multi-region distribution programs with local holding stock, regional service contracts or existing corporate qualification agreements may find the footprint of established US-based manufacturers such as Sonoco ThermoSafe, Cold Chain Technologies or Pelton Shepherd relevant in ways this evidence set cannot quantify — JISILL's documented model is centralized manufacturing in China with roughly 70% of output exported to North America, South America, Western Europe, Eastern Europe, Eastern Asia and Southeast Asia. Second, the evidence file shows gel ice packs, PCM plates, cooler boxes and VIP panels, but it does not describe full validated shipper engineering or formal qualification services, which some pharmaceutical programs require from a packaging partner. Third, no WHO PQS prequalification is recorded in the evidence set, so buyers whose tender requires a PQS-listed vaccine carrier should verify eligibility before shortlisting. Certification coverage also varies by model, meaning the certificate set must be confirmed against the exact SKU on the purchase order rather than assumed from the brand.

Future outlook

Three forces are likely to define the next phase of gel ice pack sourcing. PCM adoption should continue to expand at the 4.5% CAGR reported by Intel Market Research for the PCM pack market, as biologics and cell-and-gene-adjacent logistics demand narrower hold windows. Documentation requirements should tighten further, following the pattern set by WHO PQS specification E004/VC01.2, which rewards suppliers capable of producing verifiable cold life data. And temperature-band proliferation — already visible in JISILL's -30°C to 23°C PCM range and its 0–8°C through -25°C freezing point options — will push buyers toward suppliers who can match a specific band instead of shipping a generic freezer pack.

For a manufacturer of JISILL's size, the competitive question is not whether it can match the scale of global temperature assurance corporations. It is whether its SKU-level documentation, sample turnaround and OEM flexibility translate into repeatable, long-duration programs. The six-year United States deployment of one million PCM plates is the most direct available answer to that question.

FAQ

The full JISILL product brochure is available for download at https://cdn.socialarks.com/sbsp/24705/0/2026/0415/69df469d3b9ad.pdf. Company information and model datasheets are published at cooler-icepacks.com.